Clinical trials: SARS-CoV 2
COVID-19, SARS-CoV 2
Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)
The present Diagnostic Accuracy study aims at experimentally validating the use of a rapid salivary test to detect SARS-CoV-2 infection in both symptomatic and asymptomatic individuals as a preliminary approach to a mass…
- Conditions
- COVID-19, SARS-CoV 2, Corona Virus Infection
- Trial name
- NCT04357327
- Testing
- rapid salivary test
- Where
- Italy
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Università degli Studi dell'Insubria
SARS CoV 2 Infection
Rutgers Pilot for PREDICT- Patient POC Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral antigen using a point-of-care (POC) Rapid…
- Trial name
- NCT05612724
- Testing
- Testing for SARS CoV2 Antigen
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
SARS CoV 2 Infection
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
- Trial name
- NCT06234956
- Testing
- BIMERVAX
- Where
- 7 sites in Spain
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Predictors of Post-COVID-19 Clinical and Cognitive Consequences
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients.
- Trial name
- SCLC (NCT06291870)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, Coronavirus Infection
Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)
Randomized, double-blind prospective trial to test the efficacy of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65…
- Conditions
- COVID-19, Coronavirus Infection, SARS CoV 2 Infection
- Trial name
- MOR2 (NCT05178173)
- Testing
- 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
COVID-19, SARS CoV 2 Infection
Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women
This study is an open-label and Phase 2b clinical trial of the COVID-19 inactivated TURKOVAC vaccine against SARS-CoV-2 in healthy pregnant women.
- Trial name
- NCT06997653
- Testing
- TURKOVAC
- Where
- Turkey (Türkiye)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
SARS CoV 2 Infection
Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.
To evaluate the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine plus a homologous boostwith Ad26.COV2.S COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonkeparticipants; vaccinated; and…
- Trial name
- Sisonke Boost (NCT05148845)
- Testing
- Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S
- Where
- 31 sites in South Africa
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Wits Health Consortium (Pty) Ltd
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
COVID-19, SARS-CoV 2
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort
DESIGN Longitudinal prospective observational multicentre study. Primary objective: Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung disease
- Conditions
- COVID-19, SARS-CoV 2, ARDS, Human, Immune System Disorder
- Trial name
- PROSAIC-19 (NCT04444609)
- Testing
- Blood tests sputum, nasal lavage and brushing
- Where
- United Kingdom
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Convalescent Plasma, COVID-19
Efficacy and Safety of COVID-19 Convalescent Plasma
Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
- Conditions
- Convalescent Plasma, COVID-19, SARS-CoV 2
- Trial name
- NCT04397523
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- North Macedonia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Transfusion Medicine of RNM
SARS-CoV 2
Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis
This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and…
- Trial name
- SAPRIS-SERO (NCT04392388)
- Testing
- Non applicable
- Where
- France
- Volunteers
- 96,883 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID-19, SARS CoV 2 Infection
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
The purpose of this study is to describe the long-term health effects of COVID-19 in a population of mostly Black and Latinx individuals and their households who were diagnosed with COVID-19 at Columbia University Irving Medical…
- Trial name
- NCT05467930
- Testing
- Survey, Medical History Review, Sample Collection
- Where
- United States
- Volunteers
- 1,520 people, healthy volunteers welcome
- Sponsor
- Columbia University
Healthcare Workers, COVID-19
TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)
A randomized parallel double-blinded placebo-controlled clinical trial to evaluate the effect of Emtricitabine/Tenofovir alafenamide (FTC/TAF) compared with placebo on the risk of developing SARS-CoV-2 disease (COVID-19) in…
- Conditions
- Healthcare Workers, COVID-19, SARS-CoV 2
- Trial name
- NCT04405271
- Testing
- Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet
- Where
- Argentina
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
SARS CoV-2 Post-Acute Sequelae
Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection
This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of…
- Trial name
- NCT05656105
- Testing
- DPA-714 PET/MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, SARS-CoV 2
SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding
Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project.
- Trial name
- SHIELD (NCT04478019)
- Testing
- 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
- Where
- United States
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma